Gabriela Senti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2443749/publications.pdf Version: 2024-02-01



CARDIELA SENITI

#	Article	IF	CITATIONS
1	Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans. Frontiers in Allergy, 2022, 3, 832010.	2.8	5
2	Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of Owners. Viruses, 2020, 12, 288.	3.3	19
3	Legal and ethical framework for global health information and biospecimen exchange - an international perspective. BMC Medical Ethics, 2020, 21, 8.	2.4	6
4	SCIM: universal single-cell matching with unpaired feature sets. Bioinformatics, 2020, 36, i919-i927.	4.1	37
5	COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. Swiss Medical Weekly, 2020, 150, w20225.	1.6	367
6	Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. Journal of Allergy and Clinical Immunology, 2019, 144, 193-203.	2.9	42
7	Intralymphatic Immunotherapy: Update and Unmet Needs. International Archives of Allergy and Immunology, 2019, 178, 141-149.	2.1	71
8	Allergen immunotherapy in allergic rhinitis: current use and future trends. Expert Review of Clinical Immunology, 2017, 13, 897-906.	3.0	27
9	Novel Allergen Immunotherapy Routes. Current Treatment Options in Allergy, 2016, 3, 102-112.	2.2	Ο
10	Novel Delivery Routes for Allergy Immunotherapy. Immunology and Allergy Clinics of North America, 2016, 36, 25-37.	1.9	34
11	Comparison of Microneedles and Adhesive-Tape Stripping in Skin Preparation for Epicutaneous Allergen Delivery. International Archives of Allergy and Immunology, 2015, 167, 103-109.	2.1	24
12	Is The Allergen Really Needed in Allergy Immunotherapy?. Current Treatment Options in Allergy, 2015, 2, 72-82.	2.2	36
13	Intralymphatic immunotherapy. World Allergy Organization Journal, 2015, 8, 9.	3.5	39
14	Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 134, 965-967.e4.	2.9	40
15	Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Review of Clinical Immunology, 2014, 10, 1059-1067.	3.0	26
16	Epicutaneous Immunotherapy for Aeroallergen and Food Allergy. Current Treatment Options in Allergy, 2014, 1, 68-78.	2.2	42
17	Influence of Phytase, EDTA, and Polyphenols on Zinc Absorption in Adults from Porridges Fortified with Zinc Sulfate or Zinc Oxide. Journal of Nutrition, 2014, 144, 1467-1473.	2.9	42
18	Intralymphatic immunotherapy: Time interval between injections is essential. Journal of Allergy and Clinical Immunology, 2014, 133, 930-931.	2.9	40

GABRIELA SENTI

#	Article	lF	CITATIONS
19	Risk Assessment of Hymenoptera Re-Sting Frequency: Implications for Decision-Making in Venom Immunotherapy. International Archives of Allergy and Immunology, 2013, 160, 86-92.	2.1	20
20	A Randomized, Double-Blind, Placebo-Controlled Study to Test the Efficacy of Topical 2-Hydroxypropyl-Beta-Cyclodextrin in the Prophylaxis of Recurrent Herpes Labialis. Dermatology, 2013, 226, 247-252.	2.1	10
21	New routes for allergen immunotherapy. Human Vaccines and Immunotherapeutics, 2012, 8, 1525-1533.	3.3	29
22	Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: AÂdouble-blind, placebo-controlled dose escalation study. Journal of Allergy and Clinical Immunology, 2012, 129, 128-135.	2.9	148
23	Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. Journal of Allergy and Clinical Immunology, 2012, 129, 1290-1296.	2.9	236
24	Intralymphatic Vaccination. , 2012, , 205-221.		1
25	Novel Administration Routes for Allergen-Specific Immunotherapy: A Review of Intralymphatic and Epicutaneous Allergen-Specific Immunotherapy. Immunology and Allergy Clinics of North America, 2011, 31, 391-406.	1.9	28
26	Intralymphatic Immunotherapy: From the Rationale to Human Applications. Current Topics in Microbiology and Immunology, 2011, 352, 71-84.	1.1	31
27	Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18055-18060.	7.1	166
28	Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 582-586.	2.3	17
29	Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. Journal of Immunotherapy, 2010, 33, 848-858.	2.4	131
30	Nickel sensitisation in mice: A critical appraisal. Journal of Dermatological Science, 2010, 58, 186-192.	1.9	5
31	Intralymphatic Injections as a New Administration Route for Allergen-Specific Immunotherapy. International Archives of Allergy and Immunology, 2009, 150, 59-65.	2.1	98
32	Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology, 2009, 124, 997-1002.	2.9	180
33	Intralymphatic immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 537-543.	2.3	75
34	Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17908-17912.	7.1	308
35	Antigen kinetics determines immune reactivity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5189-5194.	7.1	158
36	Evaluation of visual analog scales for the assessment of symptom severity in allergic rhinoconjunctivitis. Annals of Allergy, Asthma and Immunology, 2007, 98, 134-138.	1.0	11

GABRIELA SENTI

#	Article	IF	CITATIONS
37	Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. Journal of Allergy and Clinical Immunology, 2006, 117, 1470-1476.	2.9	190
38	Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine, 2006, 24, 1389-1394.	3.8	16
39	Immunotherapeutic Targeting of Allergic Disease. Inflammation and Allergy: Drug Targets, 2006, 5, 243-252.	1.8	9
40	A Cutaneous Allergen Neutralisation Test That Correlates with the Duration of Venom Immunotherapy. International Archives of Allergy and Immunology, 2006, 141, 377-383.	2.1	5
41	Immunity in response to particulate antigen-delivery systems. Advanced Drug Delivery Reviews, 2005, 57, 333-355.	13.7	277
42	Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. European Journal of Immunology, 2005, 35, 3591-3598.	2.9	46